A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Clinical trial NCT01456325 · COMPLETED

Trial details

NCT number: NCT01456325
Sponsor: Genentech, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Non-Squamous Non-Small Cell Lung Cancer

Start date: 2012-01-01
Primary completion: 2016-01-01
Enrollment: 494

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.